BTIG Analyst Reiterates Hold Rating on BioNano Genomics (BNGO)
PorAinvest
viernes, 22 de agosto de 2025, 8:24 pm ET1 min de lectura
BNGO--
In contrast, TR | OpenAI – 4o's Cira Diagnissa also issued a Hold rating for Bionano Genomics, while Maxim Group gave a Buy rating. These differing opinions highlight the varied perspectives among analysts on Bionano Genomics' potential.
The company's market capitalization is $15.31 million, and its price-to-earnings (P/E) ratio stands at -0.08, indicating that it is currently trading at a negative P/E ratio. This unusual P/E ratio suggests that the company is experiencing significant losses, which could impact its stock performance.
Bionano Genomics' stock has shown recent volatility, with a 52-week high of $33.72 and a 52-week low of $2.68. The stock's price has been above its 5, 20, and 50-day exponential moving averages, indicating a strongly bullish trend [1].
Despite the mixed analyst ratings, Bionano Genomics has shown growth potential. The company's revenue is forecast to grow at an average annual rate of 24% over the next three years, compared to a 6.0% growth forecast for the Life Sciences industry in the US [2].
Investors should carefully consider the risks associated with Bionano Genomics, as the company faces several challenges. Analysts have identified four warning signs, with two of them being particularly concerning [2].
References:
[1] https://financhill.com/stock-forecast/bngo-stock-prediction
[2] https://finance.yahoo.com/news/bionano-genomics-second-quarter-2025-142219941.html
BioNano Genomics received a Hold rating from BTIG analyst Mark Massaro, citing the company's shares closed at $4.13. Massaro has a success rate of 31.13% on recommended stocks. BioNano Genomics also received a Hold from TR | OpenAI – 4o's Cira Diagnissa, but a Buy rating from Maxim Group. The company's market cap is $15.31M and P/E ratio is -0.08.
Bionano Genomics (NASDAQ: BNGO), a biotechnology company focused on life sciences tools and services, has been the subject of varying analyst ratings. On July 2, 2025, BTIG analyst Mark Massaro assigned a Hold rating to Bionano Genomics' stock, noting that the shares closed at $4.13. Massaro's success rate for recommended stocks stands at 31.13%, indicating a cautious approach to Bionano Genomics' stock.In contrast, TR | OpenAI – 4o's Cira Diagnissa also issued a Hold rating for Bionano Genomics, while Maxim Group gave a Buy rating. These differing opinions highlight the varied perspectives among analysts on Bionano Genomics' potential.
The company's market capitalization is $15.31 million, and its price-to-earnings (P/E) ratio stands at -0.08, indicating that it is currently trading at a negative P/E ratio. This unusual P/E ratio suggests that the company is experiencing significant losses, which could impact its stock performance.
Bionano Genomics' stock has shown recent volatility, with a 52-week high of $33.72 and a 52-week low of $2.68. The stock's price has been above its 5, 20, and 50-day exponential moving averages, indicating a strongly bullish trend [1].
Despite the mixed analyst ratings, Bionano Genomics has shown growth potential. The company's revenue is forecast to grow at an average annual rate of 24% over the next three years, compared to a 6.0% growth forecast for the Life Sciences industry in the US [2].
Investors should carefully consider the risks associated with Bionano Genomics, as the company faces several challenges. Analysts have identified four warning signs, with two of them being particularly concerning [2].
References:
[1] https://financhill.com/stock-forecast/bngo-stock-prediction
[2] https://finance.yahoo.com/news/bionano-genomics-second-quarter-2025-142219941.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios